AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS 125_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS Introduction_NNP recorded_VBD as_IN goodwill_NN ._.
The_DT amount_NN allocated_VBN On_IN disposal_NN of_IN a_DT business_NN ,_, the_DT gain_NN or_CC loss_NN The_DT accompanying_VBG consolidated_JJ Financial_NNP to_TO in-process_JJ research_NN and_CC development_NN under_IN US_NNP GAAP_NNP may_MD differ_VB from_IN that_DT under_IN Statements_NNP included_VBD in_IN this_DT Annual_JJ Report_NNP was_VBD ,_, as_IN required_VBN by_IN US_NNP GAAP_NNP ,_, expensed_VBD UK_NNP GAAP_NNP due_JJ principally_RB to_TO goodwill_NN are_VBP prepared_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
immediately_RB in_IN the_DT first_JJ reporting_NN period_NN after_IN capitalized_JJ and_CC amortised_JJ ,_, together_RB with_IN the_DT There_EX are_VBP certain_JJ significant_JJ differences_NNS the_DT business_NN combination_NN ._.
Fair_NNP value_NN appropriate_JJ share_NN of_IN other_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP which_WDT adjustments_NNS to_TO the_DT recorded_VBN amount_NN of_IN between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS affect_VBP AstraZenecas_NNP net_JJ income_NN and_CC inventory_NN were_VBD expensed_VBN in_IN the_DT period_NN recognized_VBN previously_RB ._.
shareholders_NNS equity_NN and_CC ,_, on_IN pages_NNS 125_CD to_TO the_DT inventory_NN was_VBD utilised_VBN ._.
Additional_JJ 135_CD ,_, additional_JJ information_NN under_IN US_NNP GAAP_NNP amortisation_NN and_CC depreciation_NN have_VBP Capitalisation_NNP of_IN interest_NN is_VBZ set_VBN out_RP as_IN follows_VBZ :_: also_RB been_VBN recorded_VBN in_IN respect_NN of_IN the_DT fair_JJ AstraZeneca_NNP does_VBZ not_RB capitalize_VB interest_NN in_IN its_PRP$ value_NN adjustments_NNS to_TO tangible_JJ and_CC UK_NNP GAAP_NNP Financial_NNP Statements_NNP ._.
US_NNP GAAP_NNP summary_NN of_IN differences_NNS between_IN UK_NNP intangible_JJ assets_NNS ._.
requires_VBZ interest_NN incurred_VBN as_IN part_NN of_IN the_DT cost_NN and_CC US_NNP GAAP_NNP accounting_NN principles_NNS :_: of_IN constructing_VBG fixed_JJ assets_NNS to_TO be_VB capitalized_VBN page_NN 125_CD In_IN the_DT consolidated_JJ Financial_NNP Statements_NNP and_CC amortised_VBN over_IN the_DT life_NN of_IN the_DT asset_NN ._.
prepared_VBN under_IN UK_NNP GAAP_NNP ,_, goodwill_NN arising_VBG net_JJ income_NN :_: page_NN 128_CD on_IN acquisitions_NNS made_VBN prior_RB to_TO 1_CD January_NNP 1998_CD Dividends_NNPS accounted_VBD for_IN under_IN the_DT purchase_NN method_NN Under_IN UK_NNP GAAP_NNP ,_, Ordinary_NNP Share_NNP dividends_NNS US_NNP GAAP_NNP condensed_JJ consolidated_JJ has_VBZ been_VBN eliminated_VBN against_IN shareholders_NNS proposed_VBN are_VBP provided_VBN for_IN in_IN the_DT year_NN in_IN statement_NN of_IN operations_NNS :_: page_NN 129_CD equity_NN ._.
Under_IN the_DT requirements_NNS of_IN UK_NNP respect_NN of_IN which_WDT they_PRP are_VBP recommended_VBN by_IN Financial_NNP Reporting_NNP Standard_NNP 10_CD Goodwill_NNP the_DT Board_NNP of_IN Directors_NNS for_IN approval_NN by_IN the_DT US_NNP GAAP_NNP statement_NN of_IN comprehensive_JJ and_CC Intangible_JJ Assets_NNS ,_, goodwill_NN on_IN shareholders_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, such_JJ income_NN :_: page_NN 129_CD acquisitions_NNS made_VBN after_IN 1_CD January_NNP 1998_CD is_VBZ dividends_NNS are_VBP not_RB provided_VBN for_IN until_IN declared_VBN capitalized_JJ and_CC amortised_JJ over_IN its_PRP$ estimated_VBN by_IN the_DT Board_NNP ._.
stock-based_JJ compensation_NN :_: page_NN 130_CD useful_JJ life_NN which_WDT is_VBZ generally_RB presumed_VBN not_RB to_TO exceed_VB 20_CD years_NNS ._.
UK_NNP GAAP_NNP requires_VBZ that_IN Deferred_JJ taxation_NN pension_NN and_CC post-retirement_NN benefits_NNS :_: on_IN subsequent_JJ disposal_NN or_CC termination_NN of_IN a_DT Deferred_JJ taxation_NN is_VBZ provided_VBN on_IN a_DT full_JJ liability_NN page_NN 131_CD previously_RB acquired_VBN business_NN ,_, any_DT goodwill_NN basis_NN under_IN US_NNP GAAP_NNP ,_, which_WDT permits_VBZ previously_RB taken_VBN directly_RB to_TO shareholders_NNS deferred_VBN tax_NN assets_NNS to_TO be_VB recognized_VBN if_IN their_PRP$ taxation_NN :_: page_NN 133_CD equity_NN is_VBZ then_RB charged_VBN in_IN the_DT income_NN realisation_NN is_VBZ considered_VBN to_TO be_VB more_RBR likely_JJ statement_NN against_IN the_DT profit_NN or_CC loss_NN on_IN than_IN not_RB ._.
Under_IN current_JJ UK_NNP GAAP_NNP ,_, full_JJ shareholders_NNS equity_NN :_: page_NN 134_CD disposal_NN or_CC termination_NN ._.
Up_IN until_IN 1_CD January_NNP provision_NN is_VBZ also_RB made_VBN although_IN there_EX are_VBP a_DT 2002_CD ,_, under_IN US_NNP GAAP_NNP ,_, goodwill_NN was_VBD number_NN of_IN different_JJ bases_NNS on_IN which_WDT this_DT acquired_VBN intangible_JJ assets_NNS and_CC goodwill_NN :_: required_VBN to_TO be_VB capitalized_VBN and_CC amortised_VBN ._.
calculation_NN is_VBZ made_VBN ,_, for_IN example_NN rolled_VBD over_IN page_NN 134_CD Now_RB ,_, instead_RB of_IN being_VBG amortised_VBN ,_, goodwill_NN capital_NN gains_NNS ._.
is_VBZ tested_VBN annually_RB for_IN impairment_NN ._.
US_NNP GAAP_NNP condensed_JJ consolidated_JJ Pension_NN and_CC post-retirement_NN benefits_NNS statement_NN of_IN cash_NN flows_NNS :_: page_NN 135_CD Identifiable_JJ intangible_JJ assets_NNS ,_, which_WDT There_EX are_VBP four_CD main_JJ differences_NNS between_IN principally_RB include_VBP patents_NNS ,_, know-how_NN current_JJ UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP in_IN Differences_NNS between_IN UK_NNP and_CC US_NNP and_CC product_NN registrations_NNS ,_, are_VBP amortised_JJ accounting_NN for_IN pension_NN costs_NNS :_: accounting_NN principles_NNS over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS which_WDT vary_VBP between_IN five_CD years_NNS and_CC 20_CD years_NNS with_IN a_DT i_FW US_PRP GAAP_NNP requires_VBZ measurements_NNS of_IN Purchase_NN accounting_NN adjustments_NNS weighted_VBN average_JJ life_NN of_IN approximately_RB plan_NN assets_NNS and_CC obligations_NNS to_TO be_VB made_VBN Under_IN UK_NNP GAAP_NNP ,_, the_DT merger_NN of_IN Astra_NNP and_CC 13_CD years_NNS ._.
as_RB at_IN the_DT date_NN of_IN the_DT financial_JJ statements_NNS Zeneca_NNP was_VBD accounted_VBN for_IN as_IN a_DT merger_NN of_IN or_CC a_DT date_NN not_RB more_RBR than_IN three_CD months_NNS equals_VBZ pooling-of-interests_NNS ._.
Under_IN US_NNP At_IN 31_CD December_NNP 2004_CD and_CC 2003_CD under_IN US_NNP prior_RB to_TO that_DT date_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, GAAP_NNP the_DT merger_NN was_VBD accounted_VBN for_IN as_IN the_DT GAAP_NNP ,_, shareholders_NNS equity_NN includes_VBZ calculations_NNS may_MD be_VB based_VBN on_IN the_DT results_NNS acquisition_NN of_IN Astra_NNP by_IN Zeneca_NNP using_VBG capitalized_JJ goodwill_NN of_IN $_$ 16,143_CD m_NN and_CC of_IN the_DT latest_JJS actuarial_JJ valuation_NN :_: purchase_NN accounting_NN ._.
Under_IN purchase_NN $_$ 15,306_CD m_NN respectively_RB net_JJ of_IN amortisation_NN accounting_NN ,_, the_DT cost_NN of_IN the_DT investment_NN is_VBZ and_CC impairment_NN of_IN $_$ 2,698_CD m_NN and_CC $_$ 2,596_CD m_NN ii_FW US_PRP GAAP_NNP mandates_VBZ a_DT particular_JJ calculated_VBN at_IN the_DT market_NN value_NN of_IN the_DT shares_NNS and_CC capitalized_JJ identifiable_JJ intangible_JJ assets_NNS actuarial_JJ method_NN the_DT projected_VBN unit_NN issued_VBN together_RB with_IN other_JJ incidental_JJ costs_NNS of_IN $_$ 8,854_CD m_NN and_CC $_$ 9,536_CD m_NN respectively_RB net_JJ credit_NN method_NN and_CC requires_VBZ that_IN each_DT and_CC the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT acquired_VBN of_IN amortisation_NN and_CC impairment_NN of_IN $_$ 8,514_CD m_NN significant_JJ assumption_NN necessary_JJ to_TO entity_NN are_VBP recorded_VBN at_IN fair_JJ value_NN ._.
Goodwill_NN on_IN businesses_NNS determine_VBP annual_JJ pension_NN costs_NNS reflects_VBZ the_DT fair_JJ value_NN exercise_NN ,_, increases_NNS in_IN the_DT values_NNS disposed_VBD of_RP is_VBZ charged_VBN to_TO the_DT gain_NN or_CC loss_NN best_JJS estimates_NNS solely_RB with_IN regard_NN to_TO that_DT of_IN Astras_NNP tangible_JJ fixed_VBN assets_NNS and_CC inventory_NN on_IN disposal_NN ._.
UK_NNP GAAP_NNP does_VBZ were_VBD recognized_VBN and_CC values_VBZ attributed_VBN to_TO its_PRP$ not_RB mandate_VB a_DT particular_JJ method_NN ,_, but_CC in-process_JJ research_NN and_CC development_NN and_CC requires_VBZ that_IN the_DT method_NN and_CC existing_VBG products_NNS ,_, together_RB with_IN appropriate_JJ assumptions_NNS taken_VBN as_IN a_DT whole_JJ should_MD be_VB deferred_VBN taxation_NN effects_NNS ._.
The_DT difference_NN compatible_JJ and_CC lead_JJ to_TO the_DT actuarys_NNS best_JJS between_IN the_DT cost_NN of_IN investment_NN and_CC the_DT fair_JJ estimate_NN of_IN the_DT cost_NN of_IN providing_VBG the_DT value_NN of_IN the_DT assets_NNS and_CC liabilities_NNS of_IN Astra_NNP was_VBD benefits_NNS promised_VBN :_: AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 126_CD Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP such_JJ deferral_NN is_VBZ not_RB permitted_VBN except_IN in_IN between_IN the_DT standards_NNS relate_VBP to_TO accounting_VBG principles_NNS continued_VBD certain_JJ defined_VBN circumstances_NNS ._.
Under_IN FRS_NNP 1_CD ,_, the_DT Company_NN presents_VBZ its_PRP$ cash_NN flows_VBZ for_IN a_DT operating_NN iii_NN under_IN US_NNP GAAP_NNP ,_, a_DT negative_JJ pension_NN cost_NN Financial_NNP instruments_NNS and_CC hedging_VBG activities_NNS :_: b_NN dividends_NNS received_VBN from_IN joint_NN may_MD arise_VB where_WRB a_DT significant_JJ activities_NNS ventures_NNS and_CC associates_NNS :_: c_NN returns_NNS on_IN unrecognised_JJ net_JJ asset_NN or_CC gain_NN exists_VBZ at_IN Under_IN US_NNP GAAP_NNP ,_, all_DT derivative_JJ instruments_NNS investments_NNS and_CC servicing_NN of_IN finance_NN :_: the_DT time_NN of_IN implementation_NN ._.
This_DT is_VBZ should_MD be_VB recognized_VBN as_IN assets_NNS or_CC liabilities_NNS in_IN d_SYM tax_NN paid_VBN :_: e_LS capital_NN expenditure_NN and_CC required_VBN to_TO be_VB amortised_VBN on_IN a_DT straightthe_JJ balance_NN sheet_NN at_IN fair_JJ value_NN ._.
Gains_NNS and_CC financial_JJ investment_NN :_: f_LS acquisitions_NNS and_CC line_NN basis_NN over_IN the_DT average_JJ remaining_JJ losses_NNS are_VBP recognized_VBN in_IN net_JJ income_NN unless_IN disposals_NNS :_: g_VB dividends_NNS paid_VBN to_TO shareholders_NNS :_: service_NN period_NN of_IN employees_NNS ._.
Under_IN UK_NNP they_PRP are_VBP regarded_VBN as_IN hedges_NNS ._.
Under_IN UK_NNP h_VBP management_NN of_IN liquid_JJ resources_NNS :_: and_CC GAAP_NNP ,_, AstraZenecas_NNP policy_NN is_VBZ not_RB to_TO GAAP_NNP ,_, these_DT instruments_NNS are_VBP measured_VBN at_IN i_FW financing_NN ._.
95_CD requires_VBZ only_RB three_CD recognize_VBP pension_NN credits_NNS in_IN its_PRP$ Financial_NNP cost_NN and_CC gains_NNS or_CC losses_NNS deferred_VBN until_IN the_DT categories_NNS of_IN cash_NN flow_NN activity_NN being_VBG Statements_NNP unless_IN a_DT refund_NN of_IN ,_, or_CC underlying_VBG transactions_NNS occur_VBP ._.
reduction_NN in_IN ,_, contributions_NNS is_VBZ likely_JJ :_: and_CC Under_IN US_NNP GAAP_NNP ,_, marketable_JJ securities_NNS are_VBP Cash_NNP flows_VBZ from_IN taxation_NN ,_, returns_NNS on_IN iv_NN under_IN US_NNP GAAP_NNP ,_, a_DT minimum_JJ pension_NN recognized_VBN at_IN fair_JJ value_NN ,_, with_IN movements_NNS in_IN investments_NNS and_CC servicing_NN of_IN finance_NN and_CC liability_NN is_VBZ recognized_VBN through_IN other_JJ fair_JJ value_NN taken_VBN to_TO a_DT separate_JJ component_NN of_IN dividends_NNS received_VBN from_IN joint_JJ ventures_NNS and_CC comprehensive_JJ income_NN in_IN certain_JJ equity_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, such_JJ investments_NNS associates_NNS under_IN FRS_NNP 1_CD would_MD be_VB included_VBN circumstances_NNS when_WRB there_EX is_VBZ a_DT deficit_NN of_IN are_VBP held_VBN at_IN cost_NN ._.
as_IN operating_VBG activities_NNS under_IN SFAS_NNP No._NN ._.
95_CD :_: plan_NN assets_NNS relative_JJ to_TO the_DT accumulated_VBN capital_NN expenditure_NN and_CC financial_JJ investment_NN benefits_NNS obligation_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, Deferred_JJ income_NN and_CC acquisitions_NNS and_CC disposals_NNS would_MD be_VB there_EX is_VBZ no_DT such_JJ requirement_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, profits_NNS or_CC losses_NNS from_IN the_DT included_VBN as_IN investing_VBG activities_NNS :_: and_CC sale_NN of_IN product_NN related_VBN intangible_JJ assets_NNS are_VBP distributions_NNS would_MD be_VB included_VBN as_IN a_DT Restructuring_NN costs_NNS generally_RB taken_VBN to_TO other_JJ operating_NN income_NN at_IN financing_NN activity_NN under_IN SFAS_NNP No._NN ._.
Under_IN Under_IN UK_NNP GAAP_NNP ,_, provisions_NNS are_VBP made_VBN for_IN disposal_NN and_CC are_VBP stated_VBN after_IN taking_VBG account_NN FRS_NNP 1_CD cash_NN comprises_VBZ cash_NN in_IN hand_NN and_CC restructuring_NN costs_NNS once_RB a_DT detailed_JJ formal_JJ of_IN product_NN disposal_NN costs_NNS and_CC costs_NNS of_IN minor_JJ deposits_NNS repayable_JJ on_IN demand_NN ,_, less_JJR plan_NN is_VBZ in_IN place_NN and_CC valid_JJ expectations_NNS have_VBP outstanding_JJ obligations_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, overdrafts_VBZ repayable_JJ on_IN demand_NN :_: and_CC liquid_JJ been_VBN raised_VBN in_IN those_DT affected_VBN that_IN the_DT such_JJ profits_NNS are_VBP deferred_VBN and_CC recognized_VBN in_IN resources_NNS comprise_VBP current_JJ asset_NN restructuring_NN will_MD be_VB carried_VBN out_RP ._.
US_NNP GAAP_NNP the_DT income_NN statement_NN in_IN subsequent_JJ periods_NNS investments_NNS held_VBD as_IN readily_RB disposable_JJ stores_NNS requires_VBZ a_DT number_NN of_IN specific_JJ criteria_NNS to_TO be_VB until_IN all_DT disposal_NN obligations_NNS and_CC of_IN value_NN ._.
95_CD cash_NN met_VBD before_IN such_JJ costs_NNS can_MD be_VB recognized_VBN as_IN commitments_NNS have_VBP been_VBN completed_VBN ._.
equivalents_NNS ,_, comprising_VBG short_JJ term_NN highly_RB an_DT expense_NN ._.
Among_IN these_DT are_VBP the_DT liquid_JJ investments_NNS ,_, generally_RB with_IN original_JJ requirements_NNS that_IN costs_NNS associated_VBN with_IN exit_NN Stock-based_JJ compensation_NN maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ,_, are_VBP or_CC disposal_NN activities_NNS are_VBP recognized_VBN when_WRB In_IN the_DT Groups_NNS Financial_NNP Statements_NNP prepared_VBD grouped_VBN together_RB with_IN cash_NN :_: short_JJ term_NN the_DT costs_NNS are_VBP incurred_VBN rather_RB than_IN at_IN the_DT date_NN under_IN UK_NNP GAAP_NNP ,_, no_DT cost_NN is_VBZ accrued_VBN for_IN the_DT borrowings_NNS repayable_JJ on_IN demand_NN would_MD not_RB of_IN commitment_NN to_TO an_DT exit_NN or_CC disposal_NN plan_NN ._.
To_TO share_VB options_NNS awarded_VBN to_TO employees_NNS under_IN be_VB included_VBN within_IN cash_NN and_CC cash_NN equivalents_NNS the_DT extent_NN that_IN restructuring_VBG costs_NNS are_VBP related_VBN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN and_CC the_DT and_CC movements_NNS on_IN those_DT borrowings_NNS would_MD to_TO the_DT activities_NNS of_IN the_DT acquired_VBN company_NN ,_, US_NNP AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN be_VB included_VBN in_IN financing_NN activities_NNS ._.
GAAP_NNP allows_VBZ them_PRP to_TO be_VB recognized_VBN as_IN a_DT Plan_NN as_IN the_DT exercise_NN price_NN is_VBZ equivalent_JJ to_TO the_DT liability_NN upon_IN acquisition_NN ._.
market_NN value_NN at_IN the_DT date_NN of_IN grant_NN ._.
Under_IN US_NNP New_NNP accounting_NN standards_NNS GAAP_NNP ,_, the_DT cost_NN is_VBZ calculated_VBN as_IN the_DT difference_NN FIN_NNP No._NN ._.
46R_CD Consolidation_NN of_IN Variable_NNP Intangible_NNP assets_NNS between_IN the_DT option_NN price_NN and_CC the_DT market_NN Interest_NN Entities_NNS VIE_NNP is_VBZ intended_VBN to_TO address_VB Under_IN UK_NNP GAAP_NNP ,_, AstraZeneca_NNP capitalises_VBZ price_NN at_IN the_DT date_NN of_IN grant_NN or_CC ,_, for_IN variable_JJ perceived_VBN weaknesses_NNS in_IN accounting_NN for_IN certain_JJ defined_VBN software_NN costs_NNS and_CC amortises_NNS plans_NNS ,_, at_IN the_DT end_NN of_IN the_DT reporting_NN period_NN until_IN special_JJ purpose_NN or_CC off-balance_JJ sheet_NN entities_NNS these_DT over_IN five_CD years_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, measurement_NN date_NN ._.
Under_IN the_DT requirements_NNS and_CC provides_VBZ guidance_NN on_IN identifying_VBG the_DT software_NN costs_NNS are_VBP generally_RB capitalized_VBN and_CC of_IN APB_NNP Opinion_NNP No._NN ._.
25_CD any_DT compensation_NN primary_JJ beneficiary_NN resulting_VBG from_IN amortised_VBN over_IN three_CD to_TO five_CD years_NNS ._.
cost_NN would_MD be_VB charged_VBN over_IN the_DT period_NN from_IN arrangements_NNS or_CC financial_JJ interests_NNS as_IN the_DT date_NN the_DT options_NNS are_VBP granted_VBN to_TO the_DT date_NN opposed_VBN to_TO voting_VBG rights_NNS ._.
If_IN a_DT party_NN is_VBZ a_DT Under_IN UK_NNP GAAP_NNP certain_JJ payments_NNS for_IN rights_NNS they_PRP are_VBP first_JJ exercisable_JJ ._.
Under_IN US_NNP GAAP_NNP ,_, in_IN primary_JJ beneficiary_NN then_RB the_DT assets_NNS ,_, liabilities_NNS to_TO compounds_NNS in_IN development_NN are_VBP the_DT net_JJ income_NN reconciliation_NN ,_, the_DT Group_NNP has_VBZ and_CC results_VBZ of_IN the_DT VIE_NNP should_MD be_VB included_VBN in_IN capitalized_JJ ._.
Under_IN US_NNP GAAP_NNP these_DT adjusted_VBN for_IN stock-based_JJ compensation_NN the_DT consolidated_JJ financial_JJ statements_NNS of_IN the_DT payments_NNS are_VBP expensed_VBN ._.
costs_NNS calculated_VBN under_IN APB_NNP Opinion_NNP No._NN ._.
46R_CD applied_VBN to_TO all_DT VIEs_NNS or_CC potential_JJ VIEs_NNS referred_VBD to_TO as_IN special_JJ purpose_NN Foreign_JJ exchange_NN Statement_NN of_IN cash_NN flows_NNS :_: Basis_NN of_IN entities_NNS for_IN periods_NNS ending_VBG on_IN or_CC after_IN 15_CD Under_IN UK_NNP GAAP_NNP ,_, unrealised_JJ gains_NNS and_CC losses_NNS preparation_NN December_NNP 2003_CD ._.
Adoption_NN for_IN all_DT other_JJ on_IN foreign_JJ currency_NN transactions_NNS to_TO hedge_VB AstraZenecas_NNP statement_NN of_IN Group_NNP cash_NN flow_NN entities_NNS was_VBD required_VBN for_IN periods_NNS ending_VBG on_IN or_CC anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, foreign_JJ is_VBZ prepared_VBN in_IN accordance_NN with_IN UK_NNP Financial_NNP after_IN 15_CD March_NNP 2004_CD ._.
46R_CD did_VBD not_RB currency_NN transactions_NNS may_MD be_VB deferred_VBN and_CC Reporting_NNP Standard_NNP 1_CD Revised_VBN 1996_CD FRS_NNS have_VBP a_DT material_NN effect_NN on_IN the_DT results_NNS or_CC net_JJ accounted_VBD for_IN at_IN the_DT same_JJ time_NN as_IN the_DT 1_CD ,_, whose_WP$ objective_NN and_CC principles_NNS are_VBP similar_JJ assets_NNS of_IN AstraZeneca_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, to_TO those_DT set_VBN out_RP in_IN SFAS_NNP No._NN ._.
The_DT principal_JJ differences_NNS AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS 127_CD In_IN March_NNP 2004_CD ,_, the_DT Emerging_VBG Issues_NNS Task_NNP In_IN December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP Force_NNP EITF_NNP issued_VBD EITF_NNP Issue_NNP No._NN ._.
152_CD Accounting_NN for_IN Real_NNP Estate_NNP TimeParticipating_NNP Securities_NNPS and_CC the_DT Two-Class_NNP sharing_NN Transactions_NNS ,_, an_DT amendment_NN of_IN Method_NNP under_IN FASB_NNP Statement_NNP No._NN ._.
66_CD and_CC 67_CD which_WDT Earnings_NNS per_IN Share_NN ._.
This_DT guidance_NN provides_VBZ that_IN real_JJ estate_NN time-sharing_JJ addressed_VBD changes_NNS in_IN the_DT reporting_NN and_CC transactions_NNS should_MD be_VB accounted_VBN for_IN as_IN calculation_NN requirements_NNS for_IN earnings_NNS per_IN non-retail_JJ land_NN sales_NNS ._.
152_CD is_VBZ share_NN ,_, setting_VBG out_RP the_DT method_NN to_TO be_VB used_VBN effective_JJ for_IN fiscal_JJ years_NNS beginning_VBG after_IN when_WRB a_DT company_NN has_VBZ granted_VBN holders_NNS of_IN any_DT 15_CD June_NNP 2005_CD ._.
The_DT adoption_NN of_IN SFAS_NNP form_NN of_IN security_NN rights_NNS to_TO participate_VB in_IN the_DT No._NN ._.
152_CD is_VBZ not_RB expected_VBN to_TO have_VB a_DT material_NN earnings_NNS of_IN the_DT company_NN along_IN with_IN the_DT effect_NN on_IN the_DT net_JJ assets_NNS or_CC results_NNS of_IN participation_NN rights_NNS of_IN common_JJ stockholders_NNS ._.
The_DT adoption_NN of_IN EITF_NNP 03-6_CD had_VBD no_DT effect_NN on_IN AstraZeneca_NNP ._.
In_IN December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
153_CD Exchanges_NNS of_IN Non-monetary_JJ In_IN June_NNP 2004_CD ,_, the_DT EITF_NNP issued_VBD EITF_NNP Issue_NNP No._NN ._.
Assets_NNS ,_, an_DT amendment_NN of_IN APB_NNP Opinion_NNP No._NN ._.
03-1_CD The_DT Meaning_NNP of_IN Other_JJ Than_IN Temporary_JJ 29_CD which_WDT replaces_VBZ the_DT current_JJ exception_NN Impairment_NN and_CC Its_PRP$ Application_NN to_TO Certain_NNP from_IN fair_JJ value_NN measurement_NN for_IN nonInvestments_NNS ._.
The_DT guidance_NN details_NNS how_WRB to_TO monetary_JJ exchanges_NNS of_IN similar_JJ productive_JJ determine_VB the_DT meaning_NN of_IN other_JJ than_IN assets_NNS with_IN a_DT general_JJ exception_NN from_IN fair_JJ temporary_JJ impairment_NN and_CC its_PRP$ application_NN to_TO value_NN measurement_NN for_IN exchanges_NNS of_IN nondebt_NN and_CC equity_NN securities_NNS within_IN the_DT scope_NN of_IN monetary_JJ assets_NNS that_WDT do_VBP not_RB have_VB SFAS_NNP No._NN ._.
115_CD Accounting_NN for_IN Certain_NNP commercial_JJ substance_NN ._.
153_CD shall_MD Investments_NNPS in_IN Debt_NNP and_CC Equity_NNP Securities_NNPS be_VB applied_VBN prospectively_RB and_CC is_VBZ effective_JJ for_IN SFAS_NNP No._NN ._.
115_CD and_CC to_TO equity_NN securities_NNS that_WDT non-monetary_JJ asset_NN exchanges_NNS occurring_VBG in_IN are_VBP not_RB subject_JJ to_TO the_DT scope_NN of_IN SFAS_NNP No._NN ._.
fiscal_JJ periods_NNS beginning_VBG after_IN 15_CD June_NNP 2005_CD ._.
115_CD and_CC are_VBP not_RB accounted_VBN for_IN under_IN the_DT The_DT adoption_NN of_IN SFAS_NNP No._NN ._.
153_CD is_VBZ not_RB equity_NN method_NN of_IN accounting_NN ._.
The_DT guidance_NN expected_VBN to_TO have_VB a_DT material_NN effect_NN on_IN the_DT also_RB includes_VBZ accounting_NN considerations_NNS results_NNS or_CC net_JJ assets_NNS of_IN AstraZeneca_NNP ._.
subsequent_JJ to_TO the_DT recognition_NN of_IN an_DT impairment_NN other_JJ than_IN temporary_JJ and_CC In_IN December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP requires_VBZ certain_JJ disclosures_NNS about_IN unrealised_JJ No._NN ._.
123_CD R_NN Share-Based_NNP Payment_NN that_WDT will_MD losses_NNS that_WDT have_VBP not_RB been_VBN recognized_VBN as_IN require_VBP compensation_NN costs_NNS related_VBN to_TO shareother_JJR than_IN temporary_JJ impairments_NNS ._.
These_DT based_VBN payment_NN transactions_NNS to_TO be_VB disclosure_NN requirements_NNS became_VBD effective_JJ for_IN recognized_VBN in_IN the_DT financial_JJ statements_NNS ._.
With_IN periods_NNS ended_VBD prior_RB to_TO 30_CD June_NNP 2004_CD ._.
The_DT limited_JJ exceptions_NNS ,_, the_DT amount_NN of_IN introduction_NN of_IN recognition_NN and_CC compensation_NN cost_NN will_MD be_VB measured_VBN based_VBN measurement_NN guidance_NN of_IN EITF_NNP 03-1_CD has_VBZ on_IN the_DT grant-date_JJ fair_JJ value_NN of_IN the_DT equity_NN or_CC been_VBN deferred_VBN ._.
The_DT disclosure_NN requirements_NNS liability_NN instruments_NNS issued_VBN ._.
In_IN addition_NN ,_, liability_NN did_VBD not_RB have_VB a_DT significant_JJ effect_NN on_IN awards_NNS will_MD be_VB remeasured_VBN each_DT reporting_NN AstraZeneca_NNP :_: it_PRP is_VBZ not_RB expected_VBN that_IN the_DT period_NN ._.
Compensation_NNP cost_NN will_MD be_VB recognition_NN and_CC measurement_NN requirements_NNS recognized_VBN over_IN the_DT period_NN that_IN an_DT employee_NN will_MD have_VB a_DT material_NN impact_NN either_RB ._.
provides_VBZ service_NN in_IN exchange_NN for_IN the_DT award_NN ._.
123_CD ,_, In_IN November_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP Accounting_NNP for_IN Stock-Based_NNP No._NN ._.
151_CD Inventory_NNP Costs_NNS to_TO clarify_VB the_DT Compensation_NNP ,_, and_CC supersedes_VBZ APB_NNP accounting_NN for_IN abnormal_JJ amounts_NNS of_IN idle_JJ Opinion_NNP No._NN ._.
25_CD ,_, Accounting_NNP for_IN Stock_NNP facility_NN expense_NN ,_, freight_NN ,_, handling_VBG costs_NNS ,_, and_CC Issued_VBN to_TO Employees_NNS ._.
The_DT effective_JJ date_NN wasted_VBN material_NN spoilage_NN ._.
123_CD R_NN is_VBZ accounting_VBG periods_NNS effective_JJ for_IN inventory_NN costs_NNS incurred_VBN during_IN commencing_VBG on_IN or_CC after_IN 15_CD June_NNP 2005_CD ._.
fiscal_JJ years_NNS beginning_VBG after_IN 15_CD June_NNP 2005_CD ._.
The_DT standard_NN should_MD be_VB applied_VBN using_VBG the_DT The_DT adoption_NN of_IN SFAS_NNP No._NN ._.
151_CD is_VBZ not_RB modified_VBN prospective_JJ method_NN although_IN there_EX expected_VBN to_TO have_VB a_DT material_NN effect_NN on_IN the_DT are_VBP transitional_JJ arrangements_NNS for_IN modified_VBN results_NNS or_CC net_JJ assets_NNS of_IN AstraZeneca_NNP ._.
retrospective_JJ application_NN if_IN the_DT disclosure_NN or_CC recognition_NN requirements_NNS of_IN SFAS_NNP No._NN ._.
AstraZeneca_NNP has_VBZ not_RB yet_RB determined_VBN the_DT effect_NN of_IN the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
123_CD R._NNP AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 128_CD Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Net_JJ income_NN As_IN a_DT result_NN of_IN the_DT significant_JJ difference_NN between_IN the_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP treatment_NN of_IN the_DT combination_NN of_IN Astra_NNP and_CC Zeneca_NNP in_IN the_DT year_NN of_IN acquisition_NN ,_, and_CC in_IN the_DT results_NNS of_IN preceding_VBG periods_NNS ,_, condensed_JJ statements_NNS of_IN operations_NNS and_CC cash_NN flow_NN under_IN US_NNP GAAP_NNP have_VBP been_VBN prepared_VBN for_IN the_DT benefit_NN of_IN US_NNP investors_NNS ._.
The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT adjustments_NNS to_TO net_JJ income_NN and_CC shareholders_NNS equity_NN which_WDT would_MD have_VB been_VBN required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN ,_, as_IN shown_VBN in_IN the_DT consolidated_JJ statements_NNS of_IN income_NN before_IN exceptional_JJ items_NNS 3,527_CD 3,036_CD 3,186_CD Exceptional_JJ items_NNS after_IN tax_NN 286_CD 350_CD Net_JJ income_NN for_IN the_DT period_NN under_IN UK_NNP GAAP_NNP 3,813_CD 3,036_CD 2,836_CD Adjustments_NNS to_TO conform_VB to_TO US_NNP GAAP_NNP Purchase_NN accounting_NN adjustments_NNS including_VBG goodwill_NN and_CC intangibles_VBZ Deemed_JJ acquisition_NN of_IN Astra_NNP Amortisation_NNP and_CC other_JJ acquisition_NN adjustments_NNS 1,014_CD 952_CD 864_CD Others_NNS 49_CD 59_CD 55_CD Capitalisation_NNP ,_, less_JJR disposals_NNS and_CC amortisation_NN of_IN interest_NN 1_CD 17_CD 46_CD Deferred_JJ taxation_NN On_IN fair_JJ values_NNS of_IN Astra_NNP 283 266 239_CD Others_NNS 90_CD 91_CD 99_CD Pension_NN and_CC other_JJ post-retirement_JJ benefits_NNS expense_NN 52_CD 43_CD 46_CD Software_NNP costs_NNS 6_CD 18_CD 46_CD Stock-based_JJ compensation_NN 11_CD 12_CD 33_CD Fair_NNP value_NN of_IN financial_JJ instruments_NNS 94_CD 10_CD 93_CD Research_NNP and_CC development_NN 31_CD Deferred_JJ income_NN recognition_NN 14_CD 61_CD Unrealised_JJ losses_NNS on_IN foreign_JJ exchange_NN and_CC others_NNS 9_CD 18_CD 1_CD Net_JJ income_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 3,051_CD 2,268_CD 2,307_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS 129_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD US_NNP GAAP_NNP Condensed_NNP Consolidated_NNP Statement_NNP of_IN Operations_NNP 2004 2003 2002_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Sales_NNS 21,426_CD 18,849_CD 17,841_CD Cost_NN of_IN sales_NNS 5,150_CD 4,469_CD 4,520_CD Distribution_NN costs_NNS 177 162 141_CD Research_NNP and_CC development_NN 3,858_CD 3,451_CD 3,069_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 7,889_CD 6,941_CD 6,165_CD Amortisation_NNP of_IN intangibles_NNS 953_CD 881_CD 1,052_CD Other_JJ income_NN 534 225 308_CD Operating_NN income_NN 3,933_CD 3,170_CD 3,202_CD Net_JJ interest_NN expense_NN income_NN 1_CD 63_CD 140_CD Income_NN from_IN continuing_VBG operations_NNS before_IN taxation_NN 3,932_CD 3,233_CD 3,342_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS 881_CD 965_CD 1,035_CD Net_JJ income_NN from_IN continuing_VBG operations_NNS 3,051_CD 2,268_CD 2,307_CD Net_JJ income_NN for_IN the_DT year_NN 3,051_CD 2,268_CD 2,307_CD Weighted_VBN average_JJ number_NN of_IN $_$ 0.25_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 1,673_CD 1,709_CD 1,733_CD Dilutive_JJ impact_NN of_IN share_NN options_NNS outstanding_JJ millions_NNS 2_CD 32_CD Diluted_VBN weighted_JJ average_JJ number_NN of_IN $_$ 0.25_CD Ordinary_NNP Shares_NNP in_IN accordance_NN with_IN US_NNP GAAP_NNP millions_NNS 1,675_CD 1,712_CD 1,735_CD Net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ 1.82_CD $_$ 1.33_CD $_$ 1.33_CD US_NNP GAAP_NNP Statement_NN of_IN Comprehensive_NNP Income_NNP 2004 2003 2002_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN for_IN the_DT year_NN 3,051_CD 2,268_CD 2,307_CD Exchange_NNP gains_NNS ,_, net_NN of_IN tax_NN 2,106_CD 3,635_CD 2,919_CD Other_JJ movements_NNS ,_, net_NN of_IN tax_NN 20_CD 81_CD 73_CD Total_JJ comprehensive_JJ income_NN 5,177_CD 5,822_CD 5,153_CD Other_JJ movements_NNS in_IN 2004_CD include_VBP a_DT reduction_NN in_IN the_DT minimum_JJ liability_NN under_IN SFAS_NNP No._NN ._.
87_CD Employers_NNS Accounting_NN for_IN Pensions_NNS from_IN $_$ 39m_CD to_TO $_$ 36m_CD ._.
Tax_NNP effects_NNS on_IN exchange_NN gains_NNS losses_NNS were_VBD $_$ 82_CD m_NN and_CC on_IN other_JJ movements_NNS $_$ 27m_CD ._.
The_DT cumulative_JJ exchange_NN gains_NNS and_CC losses_NNS net_NN of_IN tax_NN on_IN the_DT translation_NN of_IN foreign_JJ currency_NN financial_JJ statements_NNS under_IN US_NNP GAAP_NNP are_VBP set_VBN out_RP in_IN the_DT following_JJ note_NN :_: 2004 2003 2002_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Balance_NN at_IN 1_CD January_NNP 2,236_CD 1,399_CD 4,318_CD Movement_NNP in_IN year_NN 2,106_CD 3,635_CD 2,919_CD Balance_NN at_IN 31_CD December_NNP 4,342_CD 2,236_CD 1,399_CD The_DT cumulative_JJ total_NN of_IN other_JJ movements_NNS net_NN of_IN tax_NN at_IN 31_CD December_NNP 2004_CD was_VBD a_DT charge_NN of_IN $_$ 134m_CD 2003_CD $_$ 154m_CD ,_, 2002_CD $_$ 73m_CD ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 130_CD Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Stock-based_JJ compensation_NN In_IN the_DT Groups_NNS Financial_NNP Statements_NNP prepared_VBD under_IN UK_NNP GAAP_NNP ,_, no_DT cost_NN is_VBZ accrued_VBN for_IN the_DT share_NN options_NNS awarded_VBN to_TO employees_NNS under_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ,_, and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN as_IN the_DT exercise_NN price_NN is_VBZ equivalent_JJ to_TO the_DT market_NN value_NN at_IN the_DT date_NN of_IN grant_NN ._.
Under_IN US_NNP GAAP_NNP the_DT cost_NN is_VBZ calculated_VBN as_IN the_DT difference_NN between_IN the_DT option_NN price_NN and_CC the_DT market_NN price_NN at_IN the_DT date_NN of_IN grant_NN or_CC ,_, for_IN variable_JJ plans_NNS ,_, at_IN the_DT end_NN of_IN the_DT reporting_NN period_NN until_IN measurement_NN date_NN ._.
Under_IN the_DT requirements_NNS of_IN APB_NNP Opinion_NNP No._NN ._.
25_CD any_DT compensation_NN cost_NN would_MD be_VB amortised_VBN over_IN the_DT period_NN from_IN the_DT date_NN the_DT options_NNS are_VBP granted_VBN to_TO the_DT date_NN they_PRP are_VBP first_JJ exercisable_JJ ._.
Under_IN US_NNP GAAP_NNP in_IN the_DT net_JJ income_NN reconciliation_NN ,_, the_DT Group_NNP has_VBZ adjusted_VBN for_IN stock_NN compensation_NN costs_NNS as_IN calculated_VBN under_IN APB_NNP Opinion_NNP No._NN ._.
123_CD Accounting_NN for_IN Stock-Based_NNP Compensation_NNP sets_VBZ out_RP an_DT alternative_JJ methodology_NN for_IN recognizing_VBG the_DT compensation_NN cost_NN based_VBN on_IN the_DT fair_JJ value_NN at_IN grant_NN date_NN ._.
Had_VBD the_DT Group_NNP adopted_VBD this_DT methodology_NN ,_, the_DT incremental_JJ effect_NN on_IN net_JJ income_NN under_IN US_NNP GAAP_NNP is_VBZ shown_VBN below_IN :_: 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN under_IN US_NNP GAAP_NNP as_IN reported_VBN 3,051_CD 2,268_CD 2,307_CD Compensation_NNP cost_NN under_IN APB_NNP No._NN ._.
25_CD 11_CD 12_CD 33_CD Compensation_NNP cost_NN under_IN SFAS_NNP No._NN ._.
123 147 154 122_CD Pro_FW forma_FW net_JJ income_NN 2,893_CD 2,126_CD 2,152_CD Pro_FW forma_FW net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_VBN :_: As_IN reported_VBN $_$ 1.82_CD $_$ 1.33_CD $_$ 1.33_CD Pro_FW forma_FW $_$ 1.73_CD $_$ 1.24_CD $_$ 1.24_CD The_DT fair_JJ value_NN of_IN options_NNS granted_VBN is_VBZ estimated_VBN ,_, based_VBN on_IN the_DT stock_NN price_NN at_IN the_DT grant_NN date_NN ,_, using_VBG the_DT Black-Scholes_NNP option_NN pricing_NN model_NN with_IN the_DT following_VBG assumptions_NNS :_: 2004 2003 2002_CD Dividend_NN yield_NN 2.3_CD %_NN 2.0_CD %_NN 1.6_CD %_NN Expected_VBN volatility_NN 25.0_CD %_NN 25.0_CD %_NN 30.0_CD %_NN Risk-free_JJ interest_NN rate_NN 3.5_CD %_NN 4.3_CD %_NN 5.2_CD %_NN Expected_VBN lives_NNS :_: AstraZeneca_NNP Share_NNP Option_NN Plan_NN 6.0_CD years_NNS 6.0_CD years_NNS 6.0_CD years_NNS Expected_VBN lives_NNS :_: SAYE_NNP Plan_NNP 3.8_CD years_NNS 4.3_CD years_NNS 4.3_CD years_NNS AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS 131_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Pension_NN and_CC post-retirement_NN benefits_NNS For_IN the_DT purposes_NNS of_IN US_NNP GAAP_NNP ,_, the_DT pension_NN information_NN as_IN set_VBN out_RP in_IN Note_NN 28_CD in_IN respect_NN of_IN the_DT UK_NNP retirement_NN plans_NNS and_CC of_IN the_DT retirement_NN plans_NNS of_IN the_DT non-UK_JJ subsidiaries_NNS has_VBZ been_VBN restated_VBN in_IN the_DT following_VBG tables_NNS in_IN accordance_NN with_IN the_DT requirements_NNS of_IN SFAS_NNP No._NN ._.
132_CD Employers_NNS Disclosures_NNS about_IN Pensions_NNS and_CC Other_JJ Postretirement_NNP Benefits_NNPS ,_, an_DT amendment_NN of_IN FASB_NNP Statements_NNP No._NN ._.
These_DT plans_NNS comprise_VBP substantially_RB all_DT of_IN the_DT actuarial_JJ liabilities_NNS of_IN all_DT AstraZeneca_NNP retirement_NN plans_NNS ._.
The_DT changes_NNS in_IN projected_VBN benefit_NN obligations_NNS ,_, plan_NN assets_NNS and_CC details_NNS of_IN the_DT funded_JJ status_NN of_IN these_DT retirement_NN plans_NNS ,_, together_RB with_IN the_DT changes_NNS in_IN the_DT accumulated_VBN other_JJ post-retirement_JJ benefit_NN obligations_NNS ,_, under_IN SFAS_NNP No._NN ._.
132_CD are_VBP as_IN follows_VBZ :_: Other_JJ Pension_NNP post-retirement_NN benefits_NNS benefits_NNS Change_NNP in_IN projected_VBN benefit_NN obligation_NN 2004 2003 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Benefit_NNP obligation_NN at_IN beginning_NN of_IN year_NN 7,416_CD 5,943_CD 242_CD 210_CD Service_NNP cost_NN 229_CD 171_CD 11_CD 9_CD Interest_NN cost_NN 385_CD 329_CD 14_CD 14_CD Participant_NN contributions_NNS 30_CD 26_CD 1_CD 1_CD Actuarial_JJ loss_NN gain_NN 328_CD 545_CD 3_CD 24_CD Special_JJ termination_NN benefits_NNS Settlement_NNP and_CC curtailment_NN 10_CD 5_CD Benefits_NNS paid_VBN 281_CD 245_CD 18_CD 19_CD Exchange_NNP 590_CD 642_CD 2_CD 3_CD Benefit_NNP obligation_NN at_IN end_NN of_IN year_NN 8,707_CD 7,416_CD 249_CD 242_CD Other_JJ Pension_NNP post-retirement_NN benefits_NNS benefits_NNS Change_NNP in_IN plan_NN assets_NNS 2004 2003 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Fair_NN value_NN at_IN beginning_NN of_IN year_NN 5,905_CD 4,549_CD 195_CD 133_CD Actual_JJ return_NN on_IN plan_NN assets_NNS 565_CD 590_CD 22_CD 35_CD Group_NNP contribution_NN 280_CD 489_CD 17_CD 43_CD Participant_NN contributions_NNS 30_CD 26_CD 1_CD Settlement_NNP and_CC curtailment_NN Benefits_NNS paid_VBD 281_CD 245_CD 17_CD 17_CD Exchange_NNP 473_CD 496_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN 6,972_CD 5,905_CD 217_CD 195_CD Funded_VBN status_NN of_IN plans_NNS 1,735_CD 1,511_CD 32_CD 47_CD Unrecognised_JJ net_JJ loss_NN 1,644_CD 1,503_CD 29_CD 36_CD Prior_RB service_NN cost_NN not_RB recognized_VBN 15_CD 25_CD 11_CD 9_CD Unrecognised_JJ net_JJ obligation_NN on_IN implementation_NN 1_CD 1_CD 25_CD 29_CD 77_CD 16_CD 11_CD 9_CD Adjustments_NNS to_TO recognize_VB minimum_JJ liability_NN :_: Intangible_JJ assets_NNS 36_CD 39_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 217_CD 260_CD Accrued_VBN benefit_NN asset_NN liability_NN 330_CD 283_CD 11_CD 9_CD At_IN 31_CD December_NNP 2004_CD ,_, the_DT projected_VBN benefit_NN obligation_NN ,_, accumulated_VBN benefit_NN obligation_NN and_CC fair_JJ value_NN of_IN the_DT plan_NN assets_NNS in_IN respect_NN of_IN the_DT pension_NN plans_NNS above_IN with_IN accumulated_VBN benefit_NN obligations_NNS in_IN excess_NN of_IN plan_NN assets_NNS were_VBD $_$ 6,699_CD m_NN ,_, $_$ 5,800_CD m_NN and_CC $_$ 5,220_CD m_NN ,_, 2003_CD $_$ 5,779_CD m_NN ,_, $_$ 4,961_CD m_NN and_CC $_$ 4,415_CD m_NN respectively_RB ._.
The_DT total_NN of_IN accumulated_VBN benefit_NN obligations_NNS for_IN the_DT pension_NN plans_NNS was_VBD $_$ 7,443_CD m_NN 2003_CD $_$ 6,239_CD m._FW The_DT measurement_NN date_NN for_IN the_DT plan_NN assets_NNS and_CC benefit_NN obligations_NNS set_VBN out_RP above_IN was_VBD 31_CD December_NNP 2004_CD ._.
Contributions_NNS to_TO the_DT plans_NNS in_IN 2005_CD are_VBP estimated_VBN to_TO be_VB $_$ 224m_CD ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 132_CD Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Assumed_JJ discount_NN rates_NNS and_CC rates_NNS of_IN increase_NN in_IN remuneration_NN used_VBN in_IN calculating_VBG the_DT projected_VBN benefit_NN obligations_NNS together_RB with_IN long_JJ term_NN rates_NNS of_IN return_NN on_IN plan_NN assets_NNS vary_VBP according_VBG to_TO the_DT economic_JJ conditions_NNS of_IN the_DT country_NN in_IN which_WDT the_DT retirement_NN plans_NNS are_VBP situated_VBN ._.
The_DT weighted_JJ average_NN rates_NNS used_VBN for_IN calculation_NN of_IN year_NN end_NN benefit_NN obligations_NNS and_CC forecast_NN benefit_NN cost_NN in_IN the_DT retirement_NN plans_NNS and_CC other_JJ benefit_NN obligations_NNS for_IN SFAS_NNP No._NN ._.
132_CD purposes_NNS were_VBD as_IN follows_VBZ :_: Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2004 2003 2002 2004_CD 2003_CD 2002_CD %_NN %_NN %_NN %_NN %_NN %_NN Discount_NNP rate_NN 5.2_CD 5.5_CD 5.8_CD 5.7_CD 5.9_CD 6.6_CD Long_JJ term_NN rate_NN of_IN increase_NN in_IN remuneration_NN 3.9_CD 4.0_CD 4.1_CD n_VBD a_DT n_NN a_DT n_NN a_DT Expected_VBN long_JJ term_NN return_NN on_IN assets_NNS 6.8_CD 6.6_CD 6.4_CD 7.8_CD 7.8_CD 7.8_CD The_DT Group_NNP has_VBZ assumed_VBN a_DT long_JJ term_NN rate_NN of_IN increase_NN in_IN healthcare_NN costs_NNS of_IN 8_CD %_NN ,_, reducing_VBG to_TO 4_CD %_NN ._.
Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2004 2003 2002 2004_CD 2003_CD 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ periodic_JJ cost_NN Service_NNP cost_NN present_JJ value_NN of_IN benefits_NNS accruing_VBG during_IN the_DT year_NN 229 171 146_CD 11_CD 98_CD Interest_NN cost_NN on_IN projected_VBN benefit_NN obligations_NNS 385 329 287_CD 14_CD 14_CD 14_CD Expected_VBN return_NN on_IN assets_NNS 406 308 276_CD 15_CD 14_CD Net_JJ amortisation_NN and_CC deferral_JJ 76_CD 45_CD 34_CD 3_CD 2_CD 1_CD Net_JJ periodic_JJ cost_NN for_IN the_DT year_NN 284 237 191_CD 13_CD 11_CD 21_CD It_PRP is_VBZ estimated_VBN that_IN a_DT one_CD percentage_NN point_NN change_NN in_IN the_DT weighted_JJ average_JJ healthcare_NN costs_NNS trend_NN would_MD have_VB the_DT following_JJ effects_NNS on_IN the_DT accumulated_VBN benefit_NN obligation_NN and_CC net_JJ periodic_JJ cost_NN at_IN 31_CD December_NNP 2004_CD :_: One_CD percentage_NN point_NN Increase_VBP Decrease_NN $_$ m_CD $_$ m_CD Accumulated_VBN benefit_NN obligation_NN 15_CD 13_CD Net_JJ periodic_JJ cost_NN 2_CD 2_CD The_DT weighted_JJ average_JJ allocation_NN of_IN pension_NN and_CC other_JJ post-retirement_JJ plan_NN assets_NNS was_VBD as_IN follows_VBZ :_: 2004_CD 2003_CD %_NN %_NN Equities_NNS 49.7_CD 49.2_CD Bonds_NNS 36.0_CD 48.8_CD Other_JJ 14.3_CD 2.0_CD The_DT benefits_NNS expected_VBN to_TO be_VB paid_VBN in_IN the_DT future_NN are_VBP as_IN follows_VBZ :_: $_$ m_CD 2005 326 2006 337_CD 2007 349 2008 362_CD 2009 376 2010 2014_CD 1,761_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS 133_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Taxation_NNP 2004 2003 2002_CD Years_NNS ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS UK_NNP taxation_NN Corporation_NNP tax_NN 379 138 165_CD Double_RB taxation_NN relief_NN 22_CD 23_CD 7_CD Adjustment_NNP in_IN respect_NN of_IN prior_JJ period_NN 178_CD Deferred_JJ taxation_NN 47_CD 88_CD 40_CD Overseas_JJ taxation_NN Overseas_JJ taxes_NNS 992 878 921_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 7_CD 35_CD 51_CD Deferred_JJ taxation_NN 250_CD 151_CD 33_CD Share_NN of_IN taxation_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS 881_CD 965_CD 1,035_CD The_DT table_NN below_IN reconciles_NNS the_DT UK_NNP statutory_JJ tax_NN charge_NN with_IN the_DT Groups_NNS actual_JJ charge_NN on_IN income_NN from_IN continuing_VBG operations_NNS ._.
2004 2003 2002_CD Years_NNS ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Income_NN on_IN continuing_VBG operations_NNS 3,932_CD 3,233_CD 3,342_CD Taxation_NNP charge_NN at_IN UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN for_IN 2004_CD 30_CD %_NN for_IN 2003_CD ,_, 30_CD %_NN for_IN 2002_CD 1,180_CD 970_CD 1,002_CD Differences_NNS in_IN effective_JJ overseas_JJ tax_NN rates_NNS 27_CD 41_CD 6_CD Items_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 40_CD 89_CD 83_CD Items_NNS not_RB chargeable_JJ for_IN tax_NN purposes_NNS 71_CD 88_CD 110_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 171_CD 35_CD 51_CD Exceptional_JJ items_NNS 124_CD 105_CD Tax_NNP on_IN income_NN from_IN continuing_VBG operations_NNS 881_CD 965_CD 1,035_CD In_IN 2004_CD ,_, claims_VBZ amounting_VBG to_TO $_$ nil_JJ 2003_CD $_$ 95m_CD for_IN tax_NN relief_NN were_VBD made_VBN arising_VBG as_IN a_DT result_NN of_IN a_DT restructuring_NN of_IN the_DT AMI_NNP joint_JJ venture_NN in_IN 1998_CD ._.
Under_IN US_NNP GAAP_NNP ,_, these_DT reliefs_NNS are_VBP adjusted_VBN against_IN the_DT goodwill_NN arising_VBG on_IN the_DT restructuring_NN and_CC included_VBD in_IN other_JJ adjustments_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 134_CD Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Shareholders_NNS equity_NN 2004_CD 2003_CD $_$ m_CD $_$ m_CD Total_JJ shareholders_NNS equity_NN under_IN UK_NNP GAAP_NNP 14,418_CD 13,178_CD Adjustments_NNS to_TO conform_VB to_TO US_NNP GAAP_NNP Purchase_NN accounting_NN adjustments_NNS including_VBG goodwill_NN and_CC intangibles_VBZ Deemed_JJ acquisition_NN of_IN Astra_NNP Goodwill_NNP 15,099_CD 14,311_CD Tangible_JJ and_CC intangible_JJ fixed_VBN assets_NNS 6,988_CD 7,661_CD Others_NNS 206_CD 145_CD Capitalisation_NNP ,_, less_JJR disposals_NNS and_CC amortisation_NN of_IN interest_NN 254_CD 255_CD Deferred_JJ taxation_NN On_IN fair_JJ value_NN of_IN Astra_NNP 2,134_CD 2,313_CD Others_NNS 92_CD 207_CD Dividend_NN 1,061_CD 914_CD Pension_NN and_CC other_JJ post-retirement_JJ benefits_NNS expense_NN 573_CD 534_CD Software_NNP costs_NNS capitalized_JJ 52_CD 46_CD Fair_NNP value_NN of_IN financial_JJ instruments_NNS 2_CD 109_CD Deferred_JJ income_NN recognition_NN Others_NNS 33_CD 89_CD Shareholders_NNS equity_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 35,314_CD 33,654_CD Acquired_VBN intangible_JJ assets_NNS Details_NNS of_IN the_DT carrying_VBG amounts_NNS of_IN intangible_JJ fixed_JJ assets_NNS and_CC past_JJ and_CC projected_VBD amortisation_NN expenses_NNS are_VBP set_VBN out_RP below_IN ._.
2004_CD 2003_CD Gross_NNP Gross_NNP carrying_VBG Accumulated_NNP carrying_VBG Accumulated_NNP amount_NN amortisation_NN amount_NN amortisation_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Product_NNP rights_NNS 14,590_CD 6,744_CD 13,733_CD 5,274_CD Marketing_NNP and_CC distribution_NN rights_NNS 1,729_CD 1,043_CD 1,659_CD 831_CD Software_NNP 589 367 462 305_CD Others_NNS 460 360 421 329_CD Total_JJ 17,368_CD 8,514_CD 16,275_CD 6,739_CD Aggregate_NNP amortisation_NN expense_NN $_$ m_CD For_IN year_NN ended_VBD 31_CD December_NNP 2004_CD 1,316_CD For_IN year_NN ended_VBD 31_CD December_NNP 2003_CD 1,245_CD For_IN year_NN ended_VBD 31_CD December_NNP 2002_CD 1,154_CD Estimated_VBN amortisation_NN expense_NN $_$ m_CD For_IN year_NN ended_VBD 31_CD December_NNP 2005_CD 1,316_CD For_IN year_NN ended_VBD 31_CD December_NNP 2006_CD 1,304_CD For_IN year_NN ended_VBD 31_CD December_NNP 2007_CD 1,216_CD For_IN year_NN ended_VBD 31_CD December_NNP 2008_CD 1,216_CD For_IN year_NN ended_VBD 31_CD December_NNP 2009_CD 1,216_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2004_CD for_IN US_NNP Investors_NNPS 135_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD The_DT weighted_JJ average_JJ amortisation_NN period_NN in_IN respect_NN of_IN each_DT class_NN of_IN intangible_JJ asset_NN is_VBZ as_IN follows_VBZ :_: Product_NN rights_NNS 13_CD years_NNS Marketing_NNP and_CC distribution_NN rights_NNS 16_CD years_NNS Software_NNP 4_CD years_NNS Other_JJ 8_CD years_NNS Goodwill_NNP The_DT changes_NNS in_IN the_DT carrying_VBG amount_NN of_IN goodwill_NN for_IN the_DT two_CD years_NNS ended_VBN 31_CD December_NNP 2004_CD were_VBD as_IN follows_VBZ :_: $_$ m_CD Balance_NN as_IN at_IN 1_CD January_NNP 2003_CD 13,647_CD Acquired_VBN 1_CD Exchange_NNP adjustments_NNS 1,658_CD Balance_NN as_IN at_IN 1_CD January_NNP 2004_CD 15,306_CD Exchange_NNP and_CC other_JJ movements_NNS 837_CD Balance_NN as_IN at_IN 31_CD December_NNP 2004_CD 16,143_CD US_NNP GAAP_NNP Condensed_NNP Consolidated_NNP Statement_NNP of_IN Cash_NNP Flows_NNP 2004 2003 2002_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cash_NN flows_VBZ from_IN operating_VBG activities_NNS 4,842_CD 3,416_CD 4,833_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS Movement_NNP in_IN short_JJ term_NN investments_NNS and_CC fixed_VBN deposits_NNS 862 771 806_CD New_NNP fixed_JJ asset_NN investments_NNS 117_CD 120_CD 1_CD Disposal_NNP of_IN fixed_JJ assets_NNS 35_CD 38_CD 66_CD Acquisitions_NNS and_CC disposals_NNS 355_CD 80_CD Capital_NNP expenditure_NN 1,183_CD 1,515_CD 1,608_CD Net_JJ cash_NN outflows_NNS from_IN investing_VBG activities_NNS 1,772_CD 746_CD 2,349_CD Net_JJ cash_NN flow_NN before_IN financing_VBG 3,070_CD 2,670_CD 2,484_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS Equity_NNP dividends_NNS paid_VBD 1,378_CD 1,222_CD 1,234_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 2,110_CD 1,107_CD 1,154_CD Net_JJ increase_NN decrease_NN in_IN short_JJ term_NN borrowings_NNS 2_CD 13_CD New_JJ loans_NNS loans_NNS repaid_VBN 725 345 105_CD Net_JJ cash_NN outflows_NNS from_IN financing_VBG activities_NNS 2,761_CD 2,674_CD 2,506_CD Increase_VBP decrease_NN in_IN cash_NN 309_CD 4_CD 22_CD Cash_NN :_: At_IN 1_CD January_NNP 581 524 510_CD Increase_VB decrease_NN in_IN cash_NN 309_CD 4_CD 22_CD Exchange_NNP movements_NNS 23_CD 61_CD 36_CD At_IN 31_CD December_NNP 913 581 524_CD Interest_NN paid_VBN was_VBD $_$ 62m_CD in_IN 2004_CD 2003_CD $_$ 32m_CD ,_, 2002_CD $_$ 96m_CD ._.
